Claudia Rössig

Research interests

Publications

• Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers

  Cancers · 2020 · 10.3390/cancers12051075

• Design and Characterization of an “All-in-One” Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines

  Cancers · 2020 · 10.3390/cancers12020375

• EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells

  Molecular Therapy · 2019 · 10.1016/j.ymthe.2019.02.014

• Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

  Leukemia · 2018 · 10.1038/s41375-018-0265-z

• Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells

  Clinical Cancer Research · 2017 · 10.1158/1078-0432.ccr-16-2138

• Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

  Blood · 2016 · 10.1182/blood-2015-09-670729

• Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G

  OncoImmunology · 2016 · 10.1080/2162402x.2016.1250050

• Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT

  Blood · 2015 · 10.1182/blood-2014-06-573725

• Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma

  Cell · 2013 · 10.1016/j.cell.2013.01.036

• The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting

  British Journal of Cancer · 2012 · 10.1038/bjc.2012.57

• Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

  Blood · 2011 · https://doi.org/10.1182/blood-2011-05-354449

• Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)–Type First-Line Therapy: A BFM-Group Study

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.34.8417

• 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells

  Clinical Cancer Research · 2009 · 10.1158/1078-0432.ccr-08-2810

• Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

  Nature Medicine · 2008 · https://doi.org/10.1038/nm.1882

• Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells

  Leukemia · 2006 · 10.1038/sj.leu.2404366

• T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

  Blood · 2006 · 10.1182/blood-2006-04-017061

• Human γδ T cells as mediators of chimaeric‐receptor redirected anti‐tumour immunity

  British Journal of Haematology · 2004 · 10.1111/j.1365-2141.2004.05077.x

• Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity

  Blood · 2002 · 10.1182/blood.v99.9.3179

• Epstein-Barr virus–specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy

  Blood · 2002 · 10.1182/blood.v99.6.2009

• Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes

  International Journal of Cancer · 2001 · https://doi.org/10.1002/ijc.1457

Current projects

No projects listed.